Annovis Bio Inc (ANVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2025 | 12-2024 | 09-2024 | 06-2024 | 03-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 22,236 | 10,552 | 12,637 | 3,998 | 3,137 |
| TOTAL | $26,737 | $13,926 | $14,362 | $5,047 | $7,813 |
| Non-Current Assets | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $26,737 | $13,926 | $14,362 | $5,047 | $7,813 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,370 | 2,306 | 4,099 | 3,395 | 4,107 |
| Accrued Expenses | 1,134 | 1,575 | 1,292 | 663 | 763 |
| TOTAL | $2,504 | $3,881 | $5,391 | $4,057 | $4,870 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 179 | 737 | 1,907 | 2,740 | 6,297 |
| TOTAL | $179 | $737 | $1,907 | $2,740 | $6,297 |
| Total Liabilities | $2,683 | $4,618 | $7,298 | $6,797 | $11,167 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 19,486 | 19,486 | 13,797 | 13,054 | 11,171 |
| Common Shares | 2 | 1 | 1 | 1 | 1 |
| Retained earnings | -140,387 | -134,850 | -128,985 | -116,346 | -111,326 |
| TOTAL | $24,054 | $9,308 | $7,064 | $-1,751 | $-3,354 |
| Total Liabilities And Equity | $26,737 | $13,926 | $14,362 | $5,046 | $7,813 |